Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Golidocitinib |
| Synonyms | |
| Therapy Description |
Golidocitinib (AZD4205) is a selective inhibitor of JAK1, which reduces downstream signaling and may lead to inhibition of cell proliferation and tumor growth (PMID: 32297743, NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Golidocitinib | AZD 4205|AZD-4205|AZD4205 | JAK1 Inhibitor 9 | Golidocitinib (AZD4205) is a selective inhibitor of JAK1, which reduces downstream signaling and may lead to inhibition of cell proliferation and tumor growth (PMID: 32297743, NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04105010 | Phase II | Golidocitinib | Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) | Completed | USA | AUS | 2 |